论文信息 - Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. - 字舞流文

Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation.

U. Boggi | P. Marchetti | F. Mosca | F. Vistoli | A. Coppelli | G. Rizzo

[1] T. Sasaki,et al. A comparison of daclizumab to ATGAM induction in simultaneous pancreas‐kidney transplant recipients on triple maintenance immunosuppression , 2000, Clinical transplantation.

[2] M. Hall,et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. , 1999, Transplantation.

[3] S. Knechtle,et al. Experience with 500 simultaneous pancreas-kidney transplants. , 1998, Annals of surgery.

[4] R. Stratta. Immunosuppression in pancreas transplantation: progress, problems and perspective. , 1998, Transplant immunology.

[5] M. Stegall,et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. , 1997, Transplantation.

[6] J. Soulillou,et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[7] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.